Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Ранг среди акций #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Цена акции
$4.74
Последняя синхронизация: 2026-08-31
Рыночная капитализация
$372.19M
Изменение (1 день)
-2.47%
Изменение (1 год)
-1.04%
Страна
US
Торговля Lexeo Therapeutics, Inc. Common Stock (LXEO)

Категория

История цены акций Lexeo Therapeutics, Inc. Common Stock (LXEO)
Наивысшая цена закрытия: $4.91 2026-08-01

Наименьшая цена закрытия: $11.06 2023-11-01
История цены акций Lexeo Therapeutics, Inc. Common Stock с 2023 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$747.04 4.70%
CH